论文部分内容阅读
目的:探讨雷贝拉唑治疗幽门螺杆菌阳性消化性溃疡的临床疗效。方法:选取我院收治的幽门螺杆菌阳性消化性溃疡患者76例,将其随机分为对照组和治疗组。对照组给予奥美拉唑治疗;治疗组给予雷贝拉唑治疗;比较两组临床疗效。结果:治疗组总有效率97.4%,明显优于对照组78.9%,组间差异(P<0.05);治疗组清除率92.1%,明显优于对照组清除率63.2%,组间差异(P<0.05)。结论:对于幽门螺杆菌阳性消化性溃疡患者,采用雷贝拉唑治疗的临床疗效确切,且幽门螺杆菌清除率高,值得临床推广及应用。
Objective: To investigate the clinical efficacy of rabeprazole in the treatment of Helicobacter pylori positive peptic ulcer. Methods: Seventy-six patients with Helicobacter pylori-positive peptic ulcer admitted to our hospital were randomly divided into control group and treatment group. The control group was treated with omeprazole; the treatment group was treated with rabeprazole; the clinical efficacy was compared between the two groups. Results: The total effective rate of the treatment group was 97.4%, which was significantly better than 78.9% of the control group (P <0.05). The clearance rate of the treatment group was 92.1%, significantly higher than that of the control group 63.2% (P < 0.05). Conclusion: For patients with Helicobacter pylori-positive peptic ulcer, the curative effect of rabeprazole is accurate, and the clearance rate of Helicobacter pylori is high, which is worthy of clinical promotion and application.